It is estimated that around two thirds of the offers on darknet markets are drug-related. Drug sales on these markets, although modest when compared to the overall retail drug market, are significant and appear to be expanding (EMCDDA)
Bibliography: Production and Supply
Supply-Side Drug Policy in the Presence of Substitutes
Evidence from the Introduction of Abuse-Deterrent Opioids (NBER)
How illegal drugs sustain organised crime in the EU (PDF)
Drug markets remain the largest criminal markets in the EU. More than one third of the criminal groups active in the EU are involved in the production, trafficking or distribution of various types of drugs (Europol, Belgium)
Developing drug supply monitoring in Europe: current concepts
This paper presents the EMCDDA’s current thinking on the conceptual framework for monitoring drug markets, crime and supply reduction — building on the work completed in this area and expanding to reflect the academic research underpinning this work and the developments observed
Drugs and the darknet: perspectives for enforcement, research and policy
A joint publication by the EMCDDA and Europol, presents the latest understanding of how darknet markets function, the threats they pose to health and security and how Europe can respond
Global Synthetic Drugs Assessment (PDF)
Amphetamine-type stimulants and new psychoactive substances (UNODC)
Drug-related intimidation – The Irish situation and international responses: an evidence review (PDF)
This report presents the findings of an evidence review on drug-related intimidation (DRI) requested by the Department of Health on behalf of the Local and Regional Drugs and Alcohol Task Forces (HRB)
The drugs situation in Ireland: an overview of trends from 2005 to 2015 (PDF)
This overview analyses ten years of data up to the most recent available with respect to the five European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) key indicators (prevalence of drug use, high risk drug use, treatment demand, drug-related deaths and mortality and drug-related infectious diseases) as well as drug-related crime and supply (Centre for Public Health at Liverpool John Moores University)
EMCDDA–Europol Joint Report on a new psychoactive substance: N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]-furan-2-carboxamide (furanylfentanyl)
The two organisations launched a data collection on this substance for the preparation of a Joint Report as stipulated by Article 5.1 of the Council Decision. The Joint Report was submitted to the Council, the Commission and the European Medicines Agency on 23 January 2017. Download
Public expenditure on supply reduction policies
This report takes a first step towards a systematic analysis, by examining a set of representative attempts to estimate public expenditure on supply reduction interventions (EMCDDA)
Public expenditure on supply reduction policies
Evaluating drug policy is an integral part of a cost-efficient approach to tackle illicit drugs. This report takes a first step towards a systematic analysis, by examining a set of representative attempts to estimate public expenditure on supply reduction interventions (Health Research Board, Ireland)
Changes in Europe’s cannabis resin market
This analysis describes how the supply of cannabis resin in Europe is changing in response to competition and other market developments (EMCDDA)
County Lines, Gangs, and Safeguarding
The Gang and Youth Violence team within the Home Office identified a growing body of intelligence, emerging in particular from London and the South East, that vulnerable young people are being exploited in order to facilitate the running of street level drug dealing within county lines (National Crime Agency)
Commission proposes a new EU Action Plan on Drugs to enhance action against drug use and trafficking
Building on the findings of the evaluation of the EU Drugs Strategy for 2013-2020 and the Action Plan for 2013-2016, the new Action Plan on Drugs provides a strengthened response to the newly-emerging health and security challenges in the area of illicit drug use and trafficking
How Big is the U.S. Market for Illegal Drugs?
Knowing the size of illegal drug markets allows us to estimate revenues going to criminal organizations, make better decisions about treatment and prevention, and evaluate drug policies (RAND)
Afghanistan Synthetic Drugs Situation Assessment (PDF)
The main objective of this report is to offer some initial insights into the extent of synthetic drug production, use, and trafficking in Afghanistan and to highlight important areas for further research (UNODC)
Highways and buyways (PDF)
A snapshot of UK drug scenes 2016 (DrugWise)
Drug supply reduction: an overview of EU policies and measures
This paper provides an overview of EU policies and responses to the production and trafficking of illicit drugs within the international context (EMCDDA)
Marketing
Alcohol is one of the most significant ‘fast moving consumer goods’ (FMCGs) marketed today. It is estimated that each year more than £800 million is spent on advertising alcoholic beverages in the UK, with the global estimate approximating $1 trillion (Institute of Alcohol Studies)
The Economics of Tobacco and Tobacco Control
This monograph, a collaboration between the National Cancer Institute and WHO, examines the current research and evidence base surrounding the economics of tobacco control—including tobacco use, tobacco growing, manufacturing and trade, tobacco product taxes and prices, and tobacco control policies and other interventions to reduce tobacco use and its consequences (WHO)
